Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isotretinoin with desloratadine versus isotretinoin alone for moderate to severe acne vulgaris
IRCT20220705055374N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acne vulgaris comparing Isotretinoin + desloratadine with Isotretinoin + placebo (2 arms). Primary endpoint: Number of acne lesions after treatment. Started Aug 2022; status: completed.
02
Drugs
isotretinoindesloratadine
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on IRCT20220705055374N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220705055374N1.